Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
Public ClinicalTrials.gov record NCT03953300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Study identification
- NCT ID
- NCT03953300
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 75 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2019
- Primary completion
- Oct 18, 2026
- Completion
- Oct 18, 2026
- Last update posted
- Aug 24, 2026
2019 – 2026
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35209 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Jacksonville | Florida | 32204 | — |
| Research Site | Miami | Florida | 33166 | — |
| Research Site | Snellville | Georgia | 30078 | — |
| Research Site | Indianapolis | Indiana | 46268 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Kansas City | Kansas | 66160 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Bloomfield Hills | Michigan | 48301 | — |
| Research Site | Rochester | Minnesota | 55905 | — |
| Research Site | St Louis | Missouri | 63156 | — |
| Research Site | Maspeth | New York | 11378 | — |
| Research Site | New Bern | North Carolina | 28562 | — |
| Research Site | Winston-Salem | North Carolina | 27104 | — |
| Research Site | Pittsburgh | Pennsylvania | 15213 | — |
| Research Site | Galveston | Texas | 77555 | — |
| Research Site | Lewisville | Texas | 75067 | — |
| Research Site | Mansfield | Texas | 76063 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03953300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03953300 live on ClinicalTrials.gov.